Table 2 The clinicopathologic characteristics of the patients of survival group and dead group
Survival (n = 71) | Dead (n = 41) | p | |
|---|---|---|---|
Age (yr) | 65.5 ± 11.5 | 70.8 ± 9.2 | 0.014a |
BMI (kg/m2) | 23.7 (21.4–26.6) | 23.4 (20.8–26.2) | 0.570b |
ORC | 50 (70.4%) | 34 (82.9%) | 0.141c |
LRC | 21 (29.6%) | 7 (17.1%) | |
Location of the tumor | 0.107c | ||
Posterior wall or trigone | 47 (66.2%) | 33 (80.5%) | |
Other location | 24 (33.8%) | 8 (19.5%) | |
Pathologic stage | 0.014c | ||
Ta and Tis and T1 | 21 (29.6%) | 7 (17.1%) | |
T2 | 30 (42.3%) | 11 (26.8%) | |
T3 and T4 | 20 (28.2%) | 23 (56.1%) | |
Pathologic nodal stage | 0.043c | ||
N0 | 65 (91.5%) | 32 (78.0%) | |
N+ | 6 (8.5%) | 9 (22.0%) | |
Negative margin | 69 (97.2%) | 38 (92.7%) | 0.159c |
Positive margin | 2 (2.8%) | 3 (7.3%) | |
No neoadjuvant/adjuvant chemotherapy | 66 (93.0%) | 29 (72.5%) | 0.004c |
Neoadjuvant/adjuvant chemotherapy | 5 (7.0%) | 11 (26.8%) |